What Was Approved?
On August 5, 2026, the FDA approved Orzeyful (oveporexton) for adults with narcolepsy type 1.
Narcolepsy type 1 is a chronic neurological disorder that can cause excessive daytime sleepiness, cataplexy, and other sleep-related symptoms.
How Is Orzeyful Different?
Orzeyful is the first approved medicine that directly targets the loss of orexin signaling, which is a key biological feature of narcolepsy type 1.
Orexin is a brain signaling system involved in maintaining wakefulness and regulating sleep.
Why Is This Approval Important?
Many existing narcolepsy treatments focus mainly on individual symptoms such as daytime sleepiness or cataplexy.
Orzeyful is the first FDA-approved treatment designed to address the disorder more broadly by targeting its underlying biology.
Who Is It For?
The approval is for adults with narcolepsy type 1.
Diagnosis and treatment should be guided by a healthcare professional familiar with sleep disorders.
What Should Patients Discuss With Their Healthcare Provider?
Patients should review:
- Current medications
- Other sleep disorders
- Possible drug interactions
- Side effects
- Driving and safety concerns
- Pregnancy or breastfeeding considerations
Bottom Line
Orzeyful (oveporexton) is a new treatment for adults with narcolepsy type 1 and represents a new approach by directly restoring orexin-related signaling.
Its approval adds an important new option for patients with this chronic sleep disorder.
Sources
- U.S. Food and Drug Administration — FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms, August 5, 2026.
- U.S. Food and Drug Administration — Novel Drug Approvals for 2026.